Mediwound (MDWD) AI Stock Analysis

• Market Cap: $208.35M
• Dividend Yield: N/A
• Average Volume (3M): 83.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: 6.15%
• EPS Growth: 34.52%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 12,821,433
• 10 Day Avg. Volume: 97,082
• 30 Day Avg. Volume: 83,890
• PEG Ratio: -0.02
• Price to Book (P/B): 5.69
• Price to Sales (P/S): 8.77
• P/FCF Ratio: -8.91
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $30.00
• Price Target Upside: 84.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $16.50 ▲(1.54% Upside)

Mediwound's overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates a bearish trend, further weighing down the score. Valuation metrics are unfavorable due to negative earnings and the absence of dividends. While the earnings call provided some positive insights into future growth potential, these are overshadowed by current financial and operational challenges.

Positive Factors

Manufacturing Expansion

The expanded manufacturing facility enhances Mediwound's ability to meet global demand, supporting long-term growth and market presence.

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, bolstering financial stability and future prospects.

Clinical Trial Progress

Advancements in clinical trials for EscharEx could lead to new market opportunities and revenue streams, enhancing long-term growth potential.

Negative Factors

Operating Losses

Rising operating losses indicate financial strain, potentially impacting future investments and operational flexibility.

Cash Flow Challenges

Persistent negative cash flows can limit Mediwound's ability to fund growth initiatives and maintain financial health.

Regulatory Uncertainty

Regulatory challenges in the EU could delay clinical trials, affecting timelines for product development and market entry.

Mediwound Business Overview & Revenue Model

Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

How the Company Makes Money

Mediwound generates revenue primarily through the sale of its medical products, most notably NexoBrid. The company sells its products directly to hospitals and healthcare facilities, often through partnerships with distributors and medical supply companies. Additionally, Mediwound may enter into licensing agreements or collaborations with larger pharmaceutical companies that can help enhance its market reach. The company also explores government and institutional contracts, which can provide significant revenue opportunities. Furthermore, Mediwound has been actively involved in clinical trials and research initiatives, which can lead to future product developments and expansions into new markets, thereby contributing to its overall revenue growth.

Mediwound Financial Statement Overview

Summary

Mediwound is facing significant financial challenges, characterized by ongoing losses, negative profit margins, and cash flow difficulties. While there is some revenue growth, the company struggles to convert this into profitability. The balance sheet shows manageable leverage, but the overall financial health is weak due to persistent losses and limited equity growth.

Income Statement

Mediwound's income statement reveals a challenging financial position with consistent net losses and negative profit margins. The TTM data shows a slight revenue growth rate of 5.41%, but the company continues to struggle with profitability, as evidenced by negative EBIT and EBITDA margins. Gross profit margin has improved slightly over the previous year, but remains low at 18.43%. Overall, the company faces significant challenges in achieving profitability.

Balance Sheet

The balance sheet indicates a moderate debt-to-equity ratio of 0.40, suggesting manageable leverage. However, the return on equity is negative, reflecting ongoing losses and a weak equity position. The equity ratio is not explicitly provided, but the overall financial health appears strained due to recurring losses and limited equity growth.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a declining free cash flow growth rate of -6.46% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a free cash flow to net income ratio above 1, the overall cash flow situation remains concerning due to persistent negative cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.93M	20.22M	18.69M	26.50M	23.76M	21.76M
Gross Profit	3.88M	1.78M	2.95M	12.32M	8.14M	7.01M
EBITDA	-10.93M	-28.12M	-4.89M	-18.09M	-12.12M	-7.99M
Net Income	-20.60M	-30.22M	-6.72M	-19.60M	-13.55M	-9.20M
Balance Sheet
Total Assets	94.42M	73.50M	66.46M	50.02M	19.74M	31.07M
Cash, Cash Equivalents and Short-Term Investments	59.09M	43.16M	41.54M	33.90M	11.05M	21.58M
Total Debt	9.33M	6.93M	6.35M	846.00K	1.39M	1.74M
Total Liabilities	34.98M	42.34M	34.86M	39.10M	24.33M	23.80M
Stockholders Equity	50.16M	31.15M	31.59M	10.91M	-4.58M	7.27M
Cash Flow
Free Cash Flow	-18.02M	-19.90M	-16.93M	-12.44M	-9.40M	-7.82M
Operating Cash Flow	-14.10M	-13.62M	-10.46M	-11.88M	-8.92M	-6.89M
Investing Cash Flow	10.12M	-8.40M	-34.32M	-481.00K	3.55M	17.39M
Financing Cash Flow	31.60M	19.39M	22.92M	35.76M	-1.05M	-629.00K

Mediwound Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Negative. The current price of 16.25 is below the 20-day moving average (MA) of 18.27, below the 50-day MA of 18.20, and below the 200-day MA of 18.50, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 33.87 is Neutral, neither overbought nor oversold. The STOCH value of 17.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDWD.

Mediwound Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTYX	63 Neutral	$996.61M	-9.26	-45.35%	―	―	36.65%
DSGN	55 Neutral	$528.62M	-7.82	-29.83%	―	―	-40.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LCTX	48 Neutral	$380.04M	―	-153.37%	―	24.05%	-169.73%
ELDN	44 Neutral	$159.18M	-1.76	-95.49%	―	―	72.35%
MDWD	43 Neutral	$208.35M	-8.56	-48.83%	―	6.15%	34.52%
TVGN	41 Neutral	$66.78M	-1.89	―	―	―	-234.46%

Mediwound Corporate Events

MediWound Lays Out Growth Path With EscharEx Progress, NexoBrid Scale-Up and Strong Cash Position

On January 12, 2026, MediWound issued a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, detailing clinical, operational and financial milestones achieved through 2025 and its outlook for the coming years. The company reported that its global Phase III VALUE trial of EscharEx in venous leg ulcers is progressing, with interim assessment and full enrollment of 216 patients across roughly 40 U.S. and European sites expected by year-end 2026, and plans to extend the program into diabetic foot ulcers via a Phase II trial and into pressure ulcers via an investigator-initiated study during 2026, supported by collaborations with several major wound care companies. MediWound also confirmed that its expanded NexoBrid manufacturing facility is now fully operational, boosting production capacity sixfold ahead of anticipated regulatory approvals in 2026, and said it expects discussions among Vericel, BARDA and U.S. authorities on a potential multi-year NexoBrid program, including stockpiling and new formulations, to move forward in early 2026. Financially, the company reported $17 million in 2025 revenue and a $54 million year-end 2025 cash position with no debt, and updated its revenue guidance to $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028, implying a step-up in long-term growth driven by NexoBrid capacity expansion, continued BARDA and U.S. Department of Defense support, and an expected initial revenue contribution from EscharEx later in the decade.

The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.

MediWound Announces Q3 2025 Financial Results and Facility Expansion

On November 20, 2025, MediWound Ltd. announced its third-quarter financial results, highlighting a 23% year-over-year revenue increase to $5.4 million. The company completed the commissioning of its expanded NexoBrid manufacturing facility, expected to reach full operational capacity by the end of 2025, significantly boosting production to meet global demand. The ongoing VALUE Phase III trial of EscharEx is progressing well, with a peak sales opportunity estimated at $831 million. MediWound also strengthened its balance sheet with $30 million in equity financing, supporting its development and commercialization efforts.

The most recent analyst rating on (MDWD) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.